SOURCE: ImmuneRegen BioSciences

March 01, 2007 07:00 ET

ImmuneRegen BioSciences Delivers Protocol for Upcoming Study With Roche's Stockpiled Antiviral Tamiflu

SCOTTSDALE, AZ -- (MARKET WIRE) -- March 1, 2007 -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBO), announced today that as a result of ImmuneRegen's recent successful study of its immunomodulator Viprovex™, which successfully prevented adverse effects from H3N2 avian influenza, that it would study Viprovex in conjunction with Tamiflu, the FDA-approved neuraminidase inhibitor used to treat, and as a pre-exposure prophylactic, to protect against influenza.

In a previous experiment performed in cotton rats at Virion Laboratories, Viprovex successfully prevented the decreases in temperature and weight in cotton rats exposed to H3N2 avian influenza. The most recent study confirmed decreases in viral titers in animal nose and lungs correlate with these indications of well-being, which were seen in Viprovex-treated animals despite influenza infection.

"In light of the reproducibility of these findings, and the cytokine data acquired previously, we feel it is prudent to commence a study adding Viprovex treatments to animals being treated post-infection or prophylactically with Tamiflu," said Hal Siegel, Ph.D. Senior Director of Product Development and Regulatory Affairs, ImmuneRegen BioSciences, Inc.

Tamiflu (oseltamivir, Roche Pharmaceuticals) is an FDA-approved treatment and prophylactic against influenza and is being purchased and stockpiled by people and governments worldwide in anticipation of a feared pandemic influenza outbreak.

ImmuneRegen's Viprovex™ has shown the ability to lower influenza viral titers in both lungs and nasal passages in a cotton rat model of influenza, as well as diminish the temperature and weight loss indications of infection. If these studies reflect an ability to treat influenza in humans, the administration in conjunction with Tamiflu might reveal additive impact on treating or preventing influenza.

About Virion Systems, Inc.

Virion Systems, Inc. (VSI) is a Maryland biotechnology corporation focused on the prevention and treatment of infectious diseases, particularly those involving infants and children. Their core technology is the use of the cotton rat as an animal model of human infectious diseases. VSI performs contract research for academic and commercial groups, centered around the use of the cotton rat (genus Sigmodon) which has been shown to be permissive for a wide array of human viral, bacterial, rickettsial and parasitic pathogens, including influenza virus (types A and B). VSI is also developing an array of cotton rat-specific reagents that will eventually include both RNA and antibody-based reagents for the detection and quantitation of cytokines, chemokines, immunoglobulins and cell-surface markers.

About Radilex™ and Viprovex™

Radilex™ is the trade name used in referring to formulations of Homspera™ for potential indications for treatment of exposure to ionizing radiation. Viprovex™ is the trade name used in referring to formulations of Homspera for potential indications for treatment of viral and bacterial infections. Homspera is a generic name used by the Company to describe the synthetic peptide Sar9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company's research and development efforts are early, pre-clinical stage and Homspera, as Viprovex™ and Radilex™, has only undergone exploratory studies to evaluate its biological activity in small animals.

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera™ and its derivatives Radilex™ and Viprovex™, which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's periodic report on Form 10-QSB for the three months ended September 30, 2006 and on Form 10-KSB for the twelve months ended December 31, 2005 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.

Contact Information